Loading company
Fortress Biotech, Inc.
FBIO · Nasdaq · ·
$2.20+0.9%Sep 29 close
- 1M
- -20.6%
- 6M
- -18.5%
- 1Y
- -40.5%
- 5Y
- -95.9%
FBIO · Nasdaq · ·
$2.20+0.9%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $18.7M | $16.4M | +14.04% |
| Profit | -$468K | $15.5M | -103.02% |
| Profit per share | -$0.08 | $0.45 | -117.78% |
| Free Cash Flow | -$12.9M | -$33.3M | +61.27% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Fortress Biotech, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Fortress Biotech, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.